Evolus, Inc. (NASDAQ:EOLS) Stock Has Average Price Target of $15.00 According to Analysts

Evolus, Inc. (NASDAQ:EOLS) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $15.00.

Several analysts have recently issued reports on EOLS shares. Wall Street Zen upgraded Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research note on Tuesday, August 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evolus in a report on Friday, September 11th. Finally, BTIG Research raised their target price on shares of Evolus from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday.

Insiders Place Their Bets

In other Evolus news, insider David Moatazedi sold 105,108 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $9.04, for a total transaction of $950,176.32. Following the completion of the transaction, the insider owned 499,592 shares of the company’s stock, valued at $4,516,311.68. The trade was a 17.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Evolus

Several hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC increased its stake in shares of Evolus by 65.6% in the third quarter. GAMMA Investing LLC now owns 3,288 shares of the company’s stock worth $26,000 after purchasing an additional 1,303 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Evolus in the 3rd quarter valued at approximately $27,000. Legal & General Group Plc acquired a new stake in Evolus in the 2nd quarter valued at approximately $40,000. Quantbot Technologies LP bought a new position in Evolus in the 2nd quarter worth approximately $56,000. Finally, Sequoia Financial Advisors LLC bought a new position in Evolus in the 2nd quarter worth approximately $71,000. 90.69% of the stock is owned by institutional investors and hedge funds.

Evolus Stock Performance

Evolus stock remained flat at $6.80 during mid-day trading on Friday. 1,521,612 shares of the company’s stock traded hands, compared to its average volume of 709,793. The firm has a market capitalization of $449.14 million, a PE ratio of -14.47 and a beta of 1.38. Evolus has a 52-week low of $3.86 and a 52-week high of $9.31. The business has a fifty day moving average price of $7.81 and a 200 day moving average price of $6.31.

About Evolus

Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for physicians and other licensed aesthetic providers. The company’s business is centered on minimally invasive treatments intended to address facial lines, wrinkles and other visible signs of aging.

Evolus’ primary product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved by the U.S. Food and Drug Administration for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines,” in adults.